Covid treatment: KMCH starts clinical trial of Favipiravir drug
Headline:
Future governments must commit sustaining reforms process: Finance Adviser
Editors’ Council voices concerns over media freedom
How AP has declared US election results since 1864
Stay alert against conspiracies, warns Fakhrul

Covid treatment: KMCH starts clinical trial of Favipiravir drug

Covid treatment: KMCH starts clinical trial of Favipiravir drug


Khulna Medical College Hospital (KMCH) has started the clinical trial of Japan’s Favipiravir drug to assess its safety and efficacy in treating Covid-19 patients.

The trial will be conducted by a team led by Dr Shailendra Nath Biswas, a junior medicine consultant of KMCH.

Former principal of KMCH Dr SK Ballabh, associate professor Dr Sheikh Farid Uddin Ahmed, indoor medical officer of the Department of Medicine Dr Tahmida Khanam, Dr Mainul Haque, Dr Rishan and Dr Abhijit will guide and assist Dr Shailendra Nath in conducting the study.

Dr Shailendra said the study will be conducted on 100 Covid-19 patients undergoing treatment at the isolation wards of KMCH and Corona-dedicated hospitals. The study will continue until September.

The effectiveness of this medicine will be determined based on the data to be obtained from the study, said Dr Shailendra.

Favipiravir, sold under the brand names Avigan, Abigan and FabiFlu, Haifukang, is an antiviral medication used to treat influenza in Japan. It is being used by some countries to treat Covid-19 patients.

Bangladesh Society of Medicine in a clinical study in Dhaka has found its effectiveness in expediting the recovery of coronavirus patients.

Subscribe UNB YouTube Channel
Khulna KMCH Khulna Medical College Hospital coronavirus coronavirus outbreak COVID-19 COVID-19 patients COVID-19 pandemic clinical trial COVID treatment